Oryzon Genomics SA (ORY)

3.040
+0.025(+0.83%)
  • Volume:
    20,248
  • Bid/Ask:
    3.040/3.070
  • Day's Range:
    2.990 - 3.080
  • Type:Equity
  • Market:Spain
  • ISIN:ES0167733015

ORY Overview

Prev. Close
3.015
Day's Range
2.99-3.08
Revenue
-
Open
2.99
52 wk Range
2.61-4.395
EPS
-0.07
Volume
20,248
Market Cap
161.45M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
94,455
P/E Ratio
-
Beta
0.63
1-Year Change
8.45%
Shares Outstanding
52,761,554
Next Earnings Date
22 Feb 2022
What is your sentiment on Oryzon Genomics SA?
or
Vote to see community's results!

Oryzon Genomics SA Company Profile

Employees
43
Market
Spain

Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellSellSellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.